PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
41.41%
Net income growth 1.25-1.5x CRWD's 30.05%. Bruce Berkowitz would verify whether cost discipline or revenue gains drive the outperformance.
4.11%
D&A growth well above CRWD's 6.21%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.72%
Both reduce yoy usage, with CRWD at -200.00%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.51%
Negative yoy usage while CRWD is 100.00%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
No Data
No Data available this quarter, please select a different quarter.
19.39%
Some CFO growth while CRWD is negative at -13.35%. John Neff would note a short-term liquidity lead over the competitor.
-26.09%
Negative yoy CapEx while CRWD is 64.44%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-146.15%
Both yoy lines negative, with CRWD at -9.26%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-16.23%
We reduce yoy invests while CRWD stands at 52.10%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-12.84%
Both yoy lines negative, with CRWD at -200.00%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
74.83%
Buyback growth of 74.83% while CRWD is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.